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Abstract
Background: In recent years, the field of vaccines for diseases such as Human Immunodeficiency Virus (HIV) which 
take a heavy toll in developing countries has faced major failures. This has led to a call for more basic science research, 
and development as well as evaluation of new vaccine candidates. Human-animal chimeras, developed with a 
'humanized' immune system could be useful to study infectious diseases, including many neglected diseases. These 
would also serve as an important tool for the efficient testing of new vaccine candidates to streamline promising 
candidates for further trials in humans. However, developing human-animal chimeras has proved to be controversial.
Discussion: Development of human-animal chimeras for vaccine development has been slowed down because of 
opposition by some philosophers, ethicists and policy makers in the west-they question the moral status of such 
animals, and also express discomfort about transgression of species barriers. Such opposition often uses a 
contemporary western world view as a reference point. Human-animal chimeras are often being created for diseases 
which cause significantly higher morbidity and mortality in the developing world as compared to the developed 
world. We argue in our commentary that given this high disease burden, we should look at socio-cultural perspectives 
on human-animal chimera like beings in the developing world. On examination, it's clear that such beings have been 
part of mythology and cultural descriptions in many countries in the developing world.
Summary: To ensure that important research on diseases afflicting millions like malaria, HIV, Hepatitis-C and dengue 
continues to progress, we recommend supporting human-animal chimera research for vaccine development in 
developing countries (especially China and India which have growing technical expertise in the area). The negative 
perceptions in some parts of the west about human-animal chimeras can be used as an opportunity for nurturing 
important vaccine development research in the developing world.
Background
The growing interest in chimeras
We need animal models that can be used to test vaccine
candidates against neglected (and less neglected) tropical
diseases such as malaria, dengue, HIV and Hepatitis C.
These diseases cause morbidity and mortality in large
numbers of people, with the developing world bearing
the heaviest burden. Vaccine candidate testing in large
non-human primates like chimpanzees is very costly, the
number of animals available is usually small and there are
concerns about inter-animal variability which affects data
interpretation; and also most jurisdictions discourage
research on large non-human primates due to ethical
concerns. Translating laboratory findings directly into
humans without adequate testing in animal models is
risky, is frowned upon by regulatory agencies, and is not
acceptable under current ethics guidelines. Human-ani-
mal chimeras provide an in-vivo system for these neces-
sary studies [1], and are developed for this purpose.
Human-animal chimeras are particularly important
because they can be made to have components which
resemble the human immune system or human liver for
early, efficient and fast testing for efficacy of new vac-
cines; this is crucial because of the unique human tro-
pism of these diseases. They can also be used for safety
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studies and to understand other effects of new technolo-
gies before they are tested in humans. As such, the cre-
ation of human-animal chimeras is more and more being
seen as a valuable experimental tool that could revolu-
tionize science and medicine [2]. They have been
described as 'indispensable' for answering fundamental
questions in stem cell and developmental biology' [3]. In
this article, we focus especially on human-animal chime-
ras and some of the issues surrounding human embry-
o n i c  s t e m  c e l l s  ( h E S C s ) ,  w h i c h  a r e  u s e d  i n  t h e i r
construction. We should note that human-animal chime-
ras of the type we discuss here are in essence xeno-trans-
plantation models, and involve engraftment of human
cells (such as blood forming progenitor cells, hepatocytes
etc.) into specially conditioned mice.
Investments have been tracked for neglected disease
research and development [4]. Evidence indicates that
human-animal chimeras have an important role in testing
new preventative vaccines not only for HIV, but also for
diseases such as dengue virus infection and other disease
[5] and for modeling the in vivo interaction of Plasmo-
dium falciparum parasites and human hepatocytes (such
studies would not be ethical to conduct in humans, and
too expensive and complex in primate models) [6]. Pro-
ducing better chimeric mice through research could lead
to a useful tool for testing new malaria vaccine candi-
d a t e s ,  a s  w e l l  a s  i n  b e t t e r  u n d e r s t a n d i n g  m a l a r i a
pathophysiology. Recent research has raised hopes that
better chimeric mouse models of infection with hepatitis-
C virus can be produced [7]. Hepatitis C infects 3 to 4
million people worldwide annually (including a signifi-
cant proportion in developing countries) adding to the
existing global burden of approximately 170 million peo-
ple (about 3% of the world's population) who are chroni-
cally infected with Hepatitis-C virus and at risk of
progressing to severe and potentially fatal liver disease,
Human-animal chimeras have been used in research for
the past few years, and have been crucial to study diseases
and developing therapies for them. For example, the
SCID-hu mouse (a chimeric immunodeficient mouse
with implanted human immune system components)
model has been used to study the following human infec-
tions [8], many of which are neglected diseases:
a) Viral: HIV, Measles, Molluscum contagiosum,
Human papillomavirus, Respiratory syncytial virus,
Hepatitis B, Hepatitis C, Varicella zoster virus, Vesic-
ular stomatitis virus, Cytomegalovirus, Herpes Sim-
plex virus, Dengue Flavivirus, Human herpesvirus-6,
Human herpesvirus-8 (Kaposi's Sarcoma), Epstein-
Barr Virus, Enteroviral endocarditis.
b) Bacterial: Helicobacter pylori, Shigella, Pseudomo-
nas (cystic fibrosis), Group A Streptococcus (impe-
tigo), Salmonella, Chlamydia trachomatis, Neisseria
meningitides
c) Parasitic: Entamoeba histolytica, Cryptosporidium
parvum, Plasmodium falciparum, Schistosoma spp.,
Trichuris spp, Toxoplasma gondii
Further work carried out in recent years on human-ani-
mal chimeras has led to the development of specific and
improved strains with applications for translational
research [9].
Major funding to develop "humanized" mouse models
for vaccine testing has been made available, for example
from the Grand Challenges in Global Health initiative
[10]. The US National Academy of Sciences has devel-
oped guidelines for the use of chimeras for research,
including mechanisms for oversight at institutions which
plan to conduct research on human-animal chimeras
[11].
But alongside growing interest in the use of chimeras
for human health there has been vocal political opposi-
tion in the West. A well known conservative US Senator
from Kansas, Sam Brownback, for example, introduced
the "Human Chimera Prohibition Act of 2005" to oppose
the use of certain kinds of human-animal chimeras [12].
While the xenotransplant chimeras under discussion here
may not necessarily fit the types of chimeras prohibited
in that act, the conflation of definitions, confusion about
terminology, and linkage to the general discussion about
human embryonic stem cells mean that public, political
and funding support for the development of human-ani-
mal chimeras generally may be compromised. This risk
was well illustrated President George W. Bush's 2006
State of the Union address, where he clearly expressed
opposition to "human-animal" hybrids. Bush asked Con-
gress to "pass legislation to prohibit the most egregious
abuses of medical research [including] creating human-
animal hybrids," because "human life is a gift from our
Creator" that should never be "devalued." [13] The situa-
tion may improve somewhat with the more pro-science
attitude of the Obama administration, but it is too early
to be sure that the negative attitudes will be reversed.
Indeed, a Gallup poll conducted in the first part of 2009
in the USA shows the lingering adverse, confused and
contradictory public perception of hESCs, which, as
noted, are commonly used for development of human-
animal chimeric mouse models for vaccine testing:
approximately 80% of respondents in the poll favored
some sort of restrictions on hESC research, and only 14%
favored no restrictions; at the same time, the poll showed
that 57% respondents viewed hESC research as "morally
acceptable" [14].
In this commentary, we recognize there are legitimate
ethical questions related to chimeras, which we review
briefly below. At the same time, the main health benefits
of chimeras may accrue in the developing world, where
views on chimeras may be more welcoming than in the
West, and where scientific capacity is growing. We pro-Bhan et al. BMC International Health and Human Rights 2010, 10:8
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pose that this concatenation of factors leads to an inter-
esting strategic opportunity of focusing a niche on
chimera research for human health in the developing
world itself.
Discussion
Ethical concerns about chimeras
Ethical reservations around the creation of human-ani-
mal chimeras have revolved around the discomfort
regarding the transgression of species boundaries [15],
and scientists have been urged to exercise restraint in the
creation of human-animal chimeras [16]. The fact that
these animals are designed to have an immune system or
other components such as hepatocytes exhibiting the
characteristics of the human immune or other physiolog-
ical system through the use of treated and differentiated
hESCs, and (probably in the future) induced pluripotent
stem (iPS) cells, has led to a number of questions. First,
what is the position of these entities in the hierarchy of
species? Secondly, what would happen if human cells
migrated to the central nervous system of such a chimera,
and there made connections with the animal's neurons
(though this is a very remote possibility given the current
status of the advances in science and the refinements
made in the protocols used)? Would the chimera then
become more "human" by developing human feelings and
fears? Would it feel oppressed in a cage but unable to
communicate its pain and anguish? These are questions
that are particularly apt in the case of "neural chimeras".
How much of the neurons would need to be replaced
with human neurons before this was a real concern, if at
all? It is not surprising, therefore, that some have argued
that human-animal chimeras have an unclear moral stat-
ure. The May 2007 issue of the American Journal of Bio-
ethics  had several articles with divergent views by
Western authors dwelling on this issue, questioning the
moral status of, and possibility of feelings, in a human
neuron mouse, and various opinions as to what extent
such research should be permitted. Other arguments
have focused on the possibility of breeding generations of
human-animal chimeras and the uncertainty of the
nature of the offspring produced. The NAS guidelines
prohibit the breeding of human-animal chimeras, where
there is a possibility of the human cells having contrib-
uted to the germ line.
A multidisciplinary working group of scientists and
bioethicists in a 2005 commentary in Science  unani-
mously rejected ethical objections to the development of
human-non human primate chimeras based on the
unnaturalness or crossing of species argument. They sup-
ported the US National Academy's stand that special
review would be appropriate to address lingering con-
cerns about cognitive and behavioral changes in the
research animals in the specific cases of human-non
human primate neural grafting [17]. In spite of these rec-
ommendations, controversy continues to plague the
research into human-animal chimeras in the West [18].
The question remains as to whether these latter positions
will prevail over the conservative ones.
Taking into account the health needs of the developing 
world
If the development of human-animal chimeras were to be
stopped or slowed down significantly because of such
positions, not only would science be held back but it
would be the developing world that would suffer most.
Though the political opposition in countries like the USA
has tended to dominate the public debate on the issues,
the perspective of developing countries in the matter of
animal human chimeras is absolutely critical.
Indeed, there is a precedence of delays in the develop-
ment of life-saving technologies when the perspective of
communities in developing countries is not taken into
account: an analogy could be drawn to the field of rotavi-
rus vaccine development. An earlier version of the rotavi-
rus vaccine was removed from the market in the US in
1999 when a few children in the West developed intus-
susceptions, which postponed plans for research and sub-
sequent introduction of rotavirus vaccines in developing
countries to the detriment of thousands, if not millions,
of children there suffering or dying from rotavirus associ-
ated diarrhea. Commenting on the issue, Weijer has
argued, and we agree, that even though there was a small
risk of intussusceptions in children getting the vaccine,
the benefits of testing the vaccine in developing coun-
tries, given the disease burden, far outweighed the risk
[19]. Subsequent experience has shown that rotavirus
vaccines have high efficacy against rotavirus gastroenteri-
tis, no increased risk of intussusceptions [20], and could
help prevent substantial morbidity and mortality espe-
cially in developing countries. These rotavirus vaccines
are very likely cost-effective, a key concern for health sys-
tems in developing countries, as illustrated by a paper
looking at Mexico as a case study [21]. The authors found
that introducing the pentavalent rotavirus vaccine in the
national immunization program could significantly bring
down rotavirus infection-related hospital admissions,
medical visits and deaths and would be a highly cost-
effective intervention according to the WHO Commis-
sion on Macroeconomics and Health Criteria.
Similarly, even though the creation of human-animal
chimeras in research makes some people uncomfortable
in the West, the benefits of creating such chimeras to
accelerate vaccine development for disease that kill many
more people in the developing world will likely be seen to
be greater than the potential risks. If the attitudes in the
West harden further, might the developing world itself
supply a solution?Bhan et al. BMC International Health and Human Rights 2010, 10:8
http://www.biomedcentral.com/1472-698X/10/8
Page 4 of 5
Developing world perspectives on chimeras welcoming
Human-animal chimeras have been part of the cultural
traditions in most parts of the world. This includes the
West, where descriptions of human shape-changers, who
changed shape yet remained human, were part of folklore
in both Christian and Jewish traditions. An example is
the description of the 'Proteus legend' by Homer as a
prophet who could change shape to various forms includ-
ing animals, if captured [22]. However, in current debates
in the west, opposition to human-animal chimeras based
on conservative political viewpoints and 'moral taboo
argument(s)' [23] is quite vocal, and influences policy
making in this area. Expanding the purview beyond
Western views on human-animal chimeras reveals sev-
eral perspectives that might provide useful insight. Hin-
duism, widely practiced in India, has several mythological
creatures in its religious pantheon that are part human
and part animal, or are animals with divine powers. These
include Ganesha, the elephant-headed god and Hanu-
man, the monkey-god. The cow is considered sacred and
is worshipped, and there are other animals, which are
associated with particular gods and considered compan-
ions (for example, Durga-lion, Ganesha-rats, Shiv-snake).
Many of these divine animals are part of mythological
stories involving the victory of good over evil in the
world, especially for the benefit of the human race. Chi-
nese mythology has reference to qilin or chi, chimeras
that symbolize Confucian values like kindness, compas-
sion, peace and prosperity [24]. This chimera was consid-
ered to be non-violent, unlike chimeras in the Greek
tradition (a source for Western philosophy), which were
considered violent and sadistic [25]. Africa, a very diverse
continent, has the use of folktales, where humans might
acquire animalistic qualities, or insects that take on
human qualities [26].
While chimeras also exist in Western mythology, the
difference is that in places like India these are not just
mythologies that were paid attention to in the past: they
are part of the realities of everyday life to this day. The
argument that such ideas may justify modern science and
technology when applied to improve human health has
been applied elsewhere, for example in the literature on
xenotransplantation [27].
Besides the presence of chimeras in their mythology,
developing countries like China and India have shown
rapid recent growth in the field of biomedical research,
including the field of chimera research with increased
funding and progress both in the public and private sec-
tor. There is already research involving human-animal
chimeras taking place in China [28,29] and there is a sig-
nificant amount of research involving hESCells in India
[30]. A comprehensive study to document the extent of
research in more developing countries has not yet been
performed, and the regulatory environments are evolving
[31].
Summary
A way forward
So what can be done to avoid the slowing down of vaccine
development because of conservative Western attitudes?
One solution would be for a dialogue between those who
hold differing views, but it is difficult to see how attitudes
could be changed rapidly enough to make any difference.
Another approach may be for the developing world, espe-
cially countries such as China and India, to make research
involving human-animal chimeras a specific niche, and to
support and fund it. This would be a way to move the sci-
entific field forward, and to aid the development of solu-
tions to important global health problems; this would
supplement the excellent work happening in the west in
this area, which is sometimes held up because of conser-
vative attitudes to human-animal chimeras. An example
for such funding, for the intended benefit of the develop-
ing world, already exists: The Bill and Melinda Gates
Foundation has funded a project at Peking University,
China, through its Grand Challenges in Global Health
Initiative, to develop a "humanized" chimeric mouse
model with an immune system and liver similar to
humans for testing and development of potential HIV
and HCV vaccine candidates [32], and provided support
to develop a regulatory structure for the project [33]. This
is in addition to the funding granted to two consortia
based in the west (Europe and the USA) as part of the
same initiative for addressing the same scientific chal-
lenge of developing (humanized chimeric mice) model
systems to evaluate live attenuated vaccine candidates.
Researchers in developing countries with relevant scien-
tific capacity such as China and India should develop
research projects with this perspective in mind, knowing
that, so long as they fulfill scientific and ethical criteria
(including humane treatment of the human-animal chi-
meras, careful planning and conduct of experiments as
well as regulation through mechanisms such as Animal
Care and Use Committees and Stem Cell Research Over-
sight Committees) for funding, they are likely to be suc-
cessful. They can turn a negative Western attitude into an
opportunity for the developing world.
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